Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease

Article Abstract:

A proliferation of neuroendocrine cells in the lungs can cause a type of obstructive lung disease. Neuroendocrine cells are not normally found in the adult lung. Six patients developed chronic lung disease characterized by coughing and shortness of breath even though none smoked or had any history of lung disease. All but one had signs of lung disease on a chest X-ray. Lung biopsies from some of the patients revealed clusters of neuroendocrine cells. In some cases, the neuroendocrine cells blocked the bronchioles and alveoli, structures that are crucial in transporting air and providing oxygen to the bloodstream. Most of the patients had relatively mild disease that had been present for years, but one 22-year-old man experienced severe lung disease that led to death from respiratory failure.

Author: Beam, William R., Aguayo, Samuel M., Miller, York E., Waldron, James A., Jr., Bogin, Robert M., Sunday, Mary E., Staton, Gerald W., Jr., King, Talmadge E., Jr.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1992
Case studies, Physiological aspects, Neurons, Respiratory tract diseases

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis

Article Abstract:

More research is needed to determine whether interferon gamma-1b is effective in treating idiopathic pulmonary fibrosis. This is a chronic inflammation of the lungs that has no known cause. Only half of all patients will still be alive five years after diagnosis. A 1999 study found that interferon gamma-1b plus prednisolone was more effective in treating idiopathic pulmonary fibrosis than prednisolone alone. All of the patients who took both drugs had an improvement in lung function.

Author: Du Bois, R.M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
Editorial

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

Article Abstract:

Interferon gamma does not appear to benefit patients with a serious lung disease called idiopathic pulmonary fibrosis, according to a study of 330 patients. After one year of treatment, symptoms, quality of life, and lung function were similar in patients who took interferon gamma and those who took a placebo, or inactive substance. Interferon gamma is a natural substance in the body that is believed to be deficient in patients with this lung disease.

Author: Schwartz, David A., King, Talmadge E., Jr., Brown, Kevin K., Raghu, Ganesh, Bradford, Williamson Z., Starko, Karen, Noble, Paul W.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Care and treatment, Interferon gamma, Pulmonary fibrosis
Similar abstracts:
  • Abstracts: Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade
  • Abstracts: Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Preeclampsia-like syndrome that is associated with severe hypothyroidism in a 20-week pregnant woman
  • Abstracts: Are the media to blame or not?. True success
  • Abstracts: Prescription drug abuse by teens increasing. Kids' mental health coverage 'limited and inadequate.' Lost in transition
  • Abstracts: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.